Treatment patterns and outcomes in CIDP, amyloidosis and GBS

• Research type

  Research Study

• Full title

  Characteristics, Treatment Patterns, and Effectiveness in CIDP, Heredofamilial Amyloidosis, and Guillain-Barré Syndrome.

• IRAS ID

  333848

• Contact name

  Michael Hughes

• Contact email

  mike.hughes@realworld.health

• Sponsor organisation

  RwHealth

• Duration of Study in the UK

  0 years, 3 months, 31 days

• Research summary

  CIDP (chronic inflammatory demyelinating polyneuropathy) is an immune-mediated peripheral nerve disorder. It can be progressive or relapsing, with sensory (loss of feeling or tingling) or motor (gradual weakening or arms and legs; loss of balance and reflexes) symptoms. It is typically diagnosed by a combination of progressive history, ruling out other neuropathic conditions, or by being refractive to immunoglobulin (a costly treatment) or corticosteroid treatment.
  The study objective is to describe the baseline demographic and clinical characteristics of CIDP, GBS and hATTR patients at a single U.K. centre to improve the understanding of the natural history of these neuropathic diseases, and to further describe the treatment outcomes of those with CIDP.

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  23/SC/0330

• Date of REC Opinion

  24 Sep 2023

• REC opinion

  Favourable Opinion